Remarkably, truncating PPM1D mutations are frequently observed in therapy-induced acute myeloid leukemia (t-AML) or myelodysplastic syndrome (t-MDS) patients [28, 29], which confers the ability of HSCs carrying the truncated PPM1D to escape cell death induced by chemotherapy. This evidence concerns the gene PPM1D and myelodysplastic syndrome.